Demand for services such as pharmaceutical research and development is picking up along with the acceleration of BD for innovative drugs going overseas. Recently, a number of CXO listed companies said at the third quarter results briefing that the company has plenty of orders in hand, and the annual performance is expected to grow. As the scale of project delivery in the fourth quarter is further expanded, industry prosperity is expected to continue.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.